 Stephanie Hsu
Concepts (181)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Vaping | 4 | 2022 | 63 | 1.060 |
Why?
| | Electronic Nicotine Delivery Systems | 4 | 2022 | 105 | 1.010 |
Why?
| | Lung Injury | 4 | 2022 | 227 | 0.930 |
Why?
| | Budesonide | 2 | 2022 | 56 | 0.810 |
Why?
| | Adrenal Insufficiency | 1 | 2022 | 29 | 0.750 |
Why?
| | Airway Extubation | 4 | 2025 | 60 | 0.680 |
Why?
| | Protein-Losing Enteropathies | 1 | 2019 | 10 | 0.630 |
Why?
| | Extracorporeal Membrane Oxygenation | 2 | 2022 | 344 | 0.610 |
Why?
| | Focal Dermal Hypoplasia | 1 | 2019 | 5 | 0.600 |
Why?
| | Failure to Thrive | 1 | 2019 | 29 | 0.600 |
Why?
| | Growth Disorders | 1 | 2019 | 87 | 0.570 |
Why?
| | Eosinophilic Esophagitis | 1 | 2022 | 328 | 0.560 |
Why?
| | Withholding Treatment | 3 | 2025 | 77 | 0.500 |
Why?
| | Glucocorticoids | 1 | 2019 | 533 | 0.460 |
Why?
| | Seizures | 2 | 2026 | 439 | 0.360 |
Why?
| | GTP-Binding Protein alpha Subunits, Gs | 2 | 2009 | 9 | 0.350 |
Why?
| | Fibrous Dysplasia, Polyostotic | 1 | 2007 | 8 | 0.270 |
Why?
| | Cystic Fibrosis Transmembrane Conductance Regulator | 2 | 2009 | 347 | 0.260 |
Why?
| | Intensive Care Units, Pediatric | 2 | 2025 | 270 | 0.250 |
Why?
| | Moyamoya Disease | 1 | 2026 | 21 | 0.240 |
Why?
| | Cerebral Revascularization | 1 | 2026 | 22 | 0.240 |
Why?
| | Child | 13 | 2025 | 22313 | 0.240 |
Why?
| | Postoperative Complications | 3 | 2026 | 2813 | 0.230 |
Why?
| | Cerebral Hemorrhage | 1 | 2026 | 116 | 0.230 |
Why?
| | Craniotomy | 1 | 2025 | 78 | 0.230 |
Why?
| | Death | 1 | 2025 | 124 | 0.220 |
Why?
| | Adolescent | 15 | 2025 | 22027 | 0.220 |
Why?
| | Retrospective Studies | 11 | 2025 | 16315 | 0.210 |
Why?
| | Child, Preschool | 9 | 2025 | 11462 | 0.210 |
Why?
| | Intraoperative Complications | 1 | 2025 | 147 | 0.210 |
Why?
| | Hypercalcemia | 1 | 2004 | 23 | 0.210 |
Why?
| | Hypocalcemia | 1 | 2004 | 35 | 0.210 |
Why?
| | Ventilator Weaning | 1 | 2023 | 39 | 0.200 |
Why?
| | Anticonvulsants | 1 | 2025 | 223 | 0.200 |
Why?
| | Lorazepam | 1 | 2023 | 25 | 0.200 |
Why?
| | Hyperparathyroidism | 1 | 2002 | 11 | 0.200 |
Why?
| | Shoulder Joint | 2 | 2019 | 177 | 0.190 |
Why?
| | Analgesia | 1 | 2023 | 102 | 0.180 |
Why?
| | Infant, Newborn | 5 | 2025 | 6257 | 0.180 |
Why?
| | Female | 22 | 2026 | 75540 | 0.180 |
Why?
| | Steroids | 1 | 2022 | 163 | 0.180 |
Why?
| | Cystic Fibrosis | 2 | 2009 | 1129 | 0.170 |
Why?
| | Glioma | 1 | 2025 | 418 | 0.170 |
Why?
| | Calcium | 2 | 2004 | 1190 | 0.170 |
Why?
| | Humans | 27 | 2026 | 140898 | 0.160 |
Why?
| | Adolescent Medicine | 1 | 2020 | 29 | 0.160 |
Why?
| | Catheter-Related Infections | 1 | 2021 | 91 | 0.160 |
Why?
| | Machine Learning | 1 | 2025 | 554 | 0.150 |
Why?
| | Endocrinology | 1 | 2020 | 76 | 0.150 |
Why?
| | Growth Hormone | 1 | 2019 | 99 | 0.150 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2019 | 97 | 0.150 |
Why?
| | Inhalation Exposure | 1 | 2020 | 108 | 0.150 |
Why?
| | Vascular Malformations | 1 | 2019 | 50 | 0.150 |
Why?
| | Capillaries | 1 | 2019 | 124 | 0.150 |
Why?
| | Urinary Tract Infections | 1 | 2021 | 193 | 0.140 |
Why?
| | Male | 17 | 2026 | 69893 | 0.140 |
Why?
| | Cross Infection | 1 | 2021 | 253 | 0.140 |
Why?
| | Respiratory Insufficiency | 1 | 2022 | 325 | 0.140 |
Why?
| | Gynecology | 1 | 2020 | 178 | 0.140 |
Why?
| | Multiple Sclerosis | 1 | 2023 | 468 | 0.140 |
Why?
| | Polycystic Ovary Syndrome | 1 | 2020 | 179 | 0.130 |
Why?
| | Fontan Procedure | 1 | 2019 | 182 | 0.130 |
Why?
| | Thyrotropin | 1 | 2017 | 117 | 0.130 |
Why?
| | Stroke | 1 | 2026 | 1158 | 0.130 |
Why?
| | Mental Health | 1 | 2023 | 753 | 0.130 |
Why?
| | Epilepsies, Myoclonic | 1 | 2017 | 57 | 0.130 |
Why?
| | Metabolic Syndrome | 1 | 2020 | 348 | 0.130 |
Why?
| | Osteoarthritis | 1 | 2019 | 203 | 0.120 |
Why?
| | Brain Neoplasms | 1 | 2025 | 1275 | 0.120 |
Why?
| | Phenotype | 2 | 2019 | 3172 | 0.120 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2017 | 318 | 0.110 |
Why?
| | Case-Control Studies | 1 | 2022 | 3578 | 0.110 |
Why?
| | Hypoglycemia | 1 | 2019 | 467 | 0.110 |
Why?
| | Sepsis | 1 | 2021 | 620 | 0.110 |
Why?
| | Developmental Disabilities | 1 | 2017 | 284 | 0.110 |
Why?
| | Young Adult | 8 | 2025 | 13646 | 0.100 |
Why?
| | Infant | 7 | 2025 | 9790 | 0.100 |
Why?
| | Testosterone | 1 | 2017 | 404 | 0.100 |
Why?
| | Hypothyroidism | 1 | 2012 | 73 | 0.090 |
Why?
| | Cohort Studies | 2 | 2019 | 5789 | 0.080 |
Why?
| | Time Factors | 4 | 2025 | 6944 | 0.080 |
Why?
| | Lung | 2 | 2022 | 4127 | 0.080 |
Why?
| | Respiration, Artificial | 2 | 2025 | 685 | 0.080 |
Why?
| | Genomic Imprinting | 1 | 2009 | 26 | 0.080 |
Why?
| | Adult | 8 | 2026 | 39134 | 0.080 |
Why?
| | Mutation | 4 | 2019 | 3999 | 0.070 |
Why?
| | Embryonic Stem Cells | 1 | 2009 | 129 | 0.070 |
Why?
| | Treatment Outcome | 5 | 2025 | 11125 | 0.070 |
Why?
| | Arthroscopy | 1 | 2009 | 245 | 0.070 |
Why?
| | Glucuronosyltransferase | 1 | 2006 | 17 | 0.060 |
Why?
| | Cyclic AMP | 1 | 2007 | 219 | 0.060 |
Why?
| | Nasal Mucosa | 1 | 2007 | 111 | 0.060 |
Why?
| | Glutathione Transferase | 1 | 2006 | 101 | 0.060 |
Why?
| | Middle Aged | 6 | 2025 | 34487 | 0.060 |
Why?
| | Cytochrome P-450 Enzyme System | 1 | 2006 | 156 | 0.060 |
Why?
| | Liver Neoplasms | 1 | 2012 | 740 | 0.060 |
Why?
| | Analgesics, Opioid | 2 | 2025 | 1114 | 0.060 |
Why?
| | Phenytoin | 1 | 2025 | 21 | 0.060 |
Why?
| | Karnofsky Performance Status | 1 | 2025 | 36 | 0.060 |
Why?
| | Cartilage, Articular | 1 | 2009 | 332 | 0.060 |
Why?
| | Neuromuscular Blockade | 1 | 2025 | 45 | 0.060 |
Why?
| | Vasoconstrictor Agents | 1 | 2025 | 136 | 0.060 |
Why?
| | Genetic Predisposition to Disease | 2 | 2019 | 2368 | 0.060 |
Why?
| | Polymerase Chain Reaction | 1 | 2007 | 1052 | 0.050 |
Why?
| | Wakefulness | 1 | 2025 | 170 | 0.050 |
Why?
| | Analgesics | 1 | 2025 | 225 | 0.050 |
Why?
| | Polymorphism, Genetic | 1 | 2006 | 624 | 0.050 |
Why?
| | Hypnotics and Sedatives | 1 | 2025 | 214 | 0.050 |
Why?
| | ROC Curve | 1 | 2025 | 589 | 0.050 |
Why?
| | Parathyroid Neoplasms | 1 | 2002 | 12 | 0.050 |
Why?
| | Parathyroid Glands | 1 | 2002 | 11 | 0.050 |
Why?
| | Tomography, Emission-Computed | 1 | 2002 | 68 | 0.050 |
Why?
| | Multiple Endocrine Neoplasia Type 2a | 1 | 2002 | 14 | 0.050 |
Why?
| | Range of Motion, Articular | 2 | 2019 | 413 | 0.050 |
Why?
| | Drug Therapy, Combination | 1 | 2025 | 1038 | 0.050 |
Why?
| | Morphine | 1 | 2023 | 162 | 0.040 |
Why?
| | Benzodiazepines | 1 | 2023 | 162 | 0.040 |
Why?
| | Urinary Catheters | 1 | 2021 | 11 | 0.040 |
Why?
| | Recovery of Function | 2 | 2019 | 680 | 0.040 |
Why?
| | United States | 3 | 2025 | 15195 | 0.040 |
Why?
| | Adenoma | 1 | 2002 | 216 | 0.040 |
Why?
| | Menopause | 1 | 2023 | 317 | 0.040 |
Why?
| | Radiography | 1 | 2002 | 844 | 0.040 |
Why?
| | Gene Expression Regulation | 1 | 2009 | 2604 | 0.040 |
Why?
| | Polymicrogyria | 1 | 2019 | 6 | 0.040 |
Why?
| | Academic Medical Centers | 1 | 2002 | 527 | 0.040 |
Why?
| | Infant, Premature | 1 | 2004 | 598 | 0.040 |
Why?
| | Tenotomy | 1 | 2019 | 19 | 0.040 |
Why?
| | Incidence | 1 | 2026 | 2782 | 0.040 |
Why?
| | Arthroplasty, Replacement, Shoulder | 1 | 2019 | 34 | 0.040 |
Why?
| | Risk Factors | 2 | 2025 | 10430 | 0.040 |
Why?
| | Osteotomy | 1 | 2019 | 124 | 0.030 |
Why?
| | NAV1.1 Voltage-Gated Sodium Channel | 1 | 2017 | 21 | 0.030 |
Why?
| | Pain | 1 | 2023 | 776 | 0.030 |
Why?
| | Prognosis | 2 | 2020 | 4060 | 0.030 |
Why?
| | Body Height | 1 | 2017 | 200 | 0.030 |
Why?
| | Follow-Up Studies | 1 | 2025 | 5194 | 0.030 |
Why?
| | Depression | 1 | 2023 | 1487 | 0.030 |
Why?
| | Signal Transduction | 1 | 2007 | 5148 | 0.030 |
Why?
| | Body Weight | 1 | 2017 | 992 | 0.020 |
Why?
| | Ranitidine | 1 | 2012 | 14 | 0.020 |
Why?
| | Aged | 2 | 2025 | 24666 | 0.020 |
Why?
| | Hemangioma | 1 | 2012 | 45 | 0.020 |
Why?
| | Thyroid Hormones | 1 | 2012 | 68 | 0.020 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2009 | 3788 | 0.020 |
Why?
| | Serum Albumin | 1 | 2012 | 152 | 0.020 |
Why?
| | Quality of Life | 1 | 2023 | 3005 | 0.020 |
Why?
| | Prednisone | 1 | 2012 | 228 | 0.020 |
Why?
| | Neoplasms | 1 | 2006 | 2718 | 0.020 |
Why?
| | Pregnancy | 1 | 2004 | 7035 | 0.020 |
Why?
| | Risk Assessment | 1 | 2020 | 3484 | 0.020 |
Why?
| | Chromogranins | 1 | 2009 | 13 | 0.020 |
Why?
| | Shoulder Impingement Syndrome | 1 | 2009 | 7 | 0.020 |
Why?
| | Administration, Oral | 1 | 2012 | 802 | 0.020 |
Why?
| | Clavicle | 1 | 2009 | 37 | 0.020 |
Why?
| | Rotator Cuff | 1 | 2009 | 47 | 0.020 |
Why?
| | Shoulder Injuries | 1 | 2009 | 59 | 0.020 |
Why?
| | Rotator Cuff Injuries | 1 | 2009 | 62 | 0.020 |
Why?
| | Adrenal Cortex Hormones | 1 | 2012 | 501 | 0.020 |
Why?
| | Chromosome Mapping | 1 | 2009 | 504 | 0.020 |
Why?
| | Twins, Dizygotic | 1 | 2009 | 163 | 0.020 |
Why?
| | Siblings | 1 | 2009 | 216 | 0.020 |
Why?
| | Twins, Monozygotic | 1 | 2009 | 190 | 0.020 |
Why?
| | Glucose Tolerance Test | 1 | 2009 | 367 | 0.020 |
Why?
| | Brain | 1 | 2019 | 2852 | 0.020 |
Why?
| | Obesity | 1 | 2020 | 3000 | 0.020 |
Why?
| | Metabolic Detoxication, Phase II | 1 | 2006 | 3 | 0.020 |
Why?
| | Metabolic Detoxication, Phase I | 1 | 2006 | 6 | 0.020 |
Why?
| | Models, Genetic | 1 | 2009 | 587 | 0.020 |
Why?
| | Reoperation | 1 | 2009 | 590 | 0.020 |
Why?
| | Prospective Studies | 1 | 2019 | 7749 | 0.020 |
Why?
| | Alleles | 1 | 2009 | 883 | 0.020 |
Why?
| | Odds Ratio | 1 | 2009 | 1054 | 0.020 |
Why?
| | Physical Therapy Modalities | 1 | 2009 | 318 | 0.020 |
Why?
| | Patient Satisfaction | 1 | 2009 | 690 | 0.010 |
Why?
| | Hyperglycemia | 1 | 2009 | 363 | 0.010 |
Why?
| | Epigenesis, Genetic | 1 | 2009 | 655 | 0.010 |
Why?
| | DNA Methylation | 1 | 2009 | 640 | 0.010 |
Why?
| | DNA | 1 | 2009 | 1438 | 0.010 |
Why?
| | Hypoglycemic Agents | 1 | 2009 | 1368 | 0.010 |
Why?
| | Insulin | 1 | 2009 | 2458 | 0.010 |
Why?
|
|
Hsu's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|